These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31511287)

  • 21. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
    Flynn KE; Myers JM; D'Souza A; Schiffer CA; Thompson JE; Atallah E
    Oncologist; 2019 Sep; 24(9):1253-1258. PubMed ID: 30944185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
    Pinilla-Ibarz J; Sweet K; Emole J; Fradley M
    Anticancer Res; 2015 Dec; 35(12):6355-64. PubMed ID: 26637844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
    Tinsley SM
    J Clin Nurs; 2010 May; 19(9-10):1207-18. PubMed ID: 20345830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
    Gunnarsson N; Stenke L; Höglund M; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Richter J; Wadenvik H; Wallvik J; Själander A
    Br J Haematol; 2015 Jun; 169(5):683-8. PubMed ID: 25817799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The importance of taking late cardiovascular toxicity induced by TKI into consideration in patients with CML].
    Takahashi N
    Rinsho Ketsueki; 2016; 57(10):1956-1961. PubMed ID: 27725593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
    Morotti A; Panuzzo C; Fava C; Saglio G
    Expert Opin Biol Ther; 2014 Mar; 14(3):287-99. PubMed ID: 24387320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.
    Gugliotta G; Castagnetti F; Fogli M; Cavo M; Baccarani M; Rosti G
    Expert Rev Hematol; 2013 Oct; 6(5):563-74. PubMed ID: 24083631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients.
    McMullan RR; McConville C; McMullin MF
    Ulster Med J; 2019 May; 88(2):105-110. PubMed ID: 31061559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Novelties and experience with tyrosine kinase inhibitor therapy in chronic myeloid leukemia].
    Gaál-Weisinger J; Mucsi O; Körösmezey G; Szili B; Eid H; Kiss R; Bödör C; Tárkányi I; Nagy Z; Demeter J
    Magy Onkol; 2017 Mar; 61(1):67-74. PubMed ID: 28273190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Breccia M; Colafigli G; Molica M; Alimena G
    Expert Opin Drug Saf; 2016; 15(4):525-33. PubMed ID: 26799331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S; Tremblay D; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current perspectives for the treatment of chronic myeloid leukemia.
    Aladağ E; Haznedaroğlu İC
    Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?
    Suttorp M; Yaniv I; Schultz KR
    Biol Blood Marrow Transplant; 2011 Jan; 17(1 Suppl):S115-22. PubMed ID: 21195300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of evidence-based treatments of fetal alcohol spectrum disorders in children and adolescents: a systematic review protocol.
    Singal D; Menard C; Neilson CJ; Brownell M; Hanlon-Dearman A; Chudley A; Zarychanski R; Abou-Setta A
    BMJ Open; 2018 Mar; 8(3):e013775. PubMed ID: 29525767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discontinuation of TKI therapy and 'functional' cure for CML.
    Mahon FX
    Best Pract Res Clin Haematol; 2016 Sep; 29(3):308-313. PubMed ID: 27839571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Management of cardiovascular complications in CML patients treated with tyrosine kinase inhibitors].
    Matsumura I
    Rinsho Ketsueki; 2018; 59(1):13-26. PubMed ID: 29415932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
    Caldemeyer L; Dugan M; Edwards J; Akard L
    Curr Hematol Malig Rep; 2016 Apr; 11(2):71-9. PubMed ID: 26922746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data.
    Irvine DA; Heaney NB; Holyoake TL
    Blood Rev; 2010 Jan; 24(1):1-9. PubMed ID: 20005615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Cuellar S; Vozniak M; Rhodes J; Forcello N; Olszta D
    J Oncol Pharm Pract; 2018 Sep; 24(6):433-452. PubMed ID: 28580869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.